射血分数改善型心力衰竭患者的临床特征和长期疗效。来自 LECRA-HF 登记处的首次抛光经验。

IF 2.5 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Konrad Stępień , Karol Nowak , Natalia Kachnic , Aleksandra Karcińska , Alicia del Carmen Yika , Jakub Furczyński , Michael Platschek , Maria Skorupa , Zuzanna Wyleciał , Jarosław Zalewski , Jadwiga Nessler
{"title":"射血分数改善型心力衰竭患者的临床特征和长期疗效。来自 LECRA-HF 登记处的首次抛光经验。","authors":"Konrad Stępień ,&nbsp;Karol Nowak ,&nbsp;Natalia Kachnic ,&nbsp;Aleksandra Karcińska ,&nbsp;Alicia del Carmen Yika ,&nbsp;Jakub Furczyński ,&nbsp;Michael Platschek ,&nbsp;Maria Skorupa ,&nbsp;Zuzanna Wyleciał ,&nbsp;Jarosław Zalewski ,&nbsp;Jadwiga Nessler","doi":"10.1016/j.advms.2024.02.009","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Heart failure (HF) with improved ejection fraction (HFimpEF) is a new category of HF introduced in the newest European Society of Cardiology guidelines. However, clinical characteristics and long-term outcomes of HFimpEF patients remain insufficiently elucidated. We sought to characterize Polish HFimpEF patients and determine their long-term mortality.</p></div><div><h3>Material and methods</h3><p>Of 1186 patients enrolled in the single-center Lesser Poland Cracovian Heart Failure (LECRA-HF) registry between 2009 and 2019 and hospitalized due to HF decompensation, 340 (28.7%) were those with HF with reduced ejection fraction (HFrEF). Based on follow-up echocardiography, 61 (17.9%) of them were classified as HFimpEF and the remaining as HFnon-impEF.</p></div><div><h3>Results</h3><p>HFimpEF patients were more frequently females (P ​&lt; ​0.001), had higher baseline left ventricular ejection fraction (LVEF, P ​&lt; ​0.001), had less often a history of diabetes (P ​= ​0.024), severe chronic kidney disease (P ​= ​0.026) or prior myocardial infarction (P ​= ​0.008) than HFnon-impEF patients. By multivariable analysis the HFimpEF diagnosis was independently predicted by baseline NYHA I/II (odds ratio [OR] 2.347, 95% confidence interval [95%CI] 1.020–5.405), non-ischemic etiology (OR 3.096, 95%CI 1.587–6.024), lack of diabetes mellitus (OR 2.016, 95%CI 1.059–3.846) and higher baseline LVEF (OR 1.084, 95%CI 1.042–1.126, per 1%). Within the median 49 (25–77) months all-cause mortality was lower in HFimpEF than in HFnon-impEF (10.8 vs 16.4%/year, P ​= ​0.004).</p></div><div><h3>Conclusions</h3><p>Our findings indicate that every sixth Polish patient with HFrEF has a chance to improve LVEF during follow-up and to become a HFimpEF patient. Baseline characteristics of HFimpEF patients are different from HFnon-impEF. Simultaneously, the HFimpEF diagnosis is associated with higher long-term survival.</p></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"69 1","pages":"Pages 132-138"},"PeriodicalIF":2.5000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical characteristics and long-term outcomes of patients with heart failure with improved ejection fraction. First Polish experience from LECRA-HF registry\",\"authors\":\"Konrad Stępień ,&nbsp;Karol Nowak ,&nbsp;Natalia Kachnic ,&nbsp;Aleksandra Karcińska ,&nbsp;Alicia del Carmen Yika ,&nbsp;Jakub Furczyński ,&nbsp;Michael Platschek ,&nbsp;Maria Skorupa ,&nbsp;Zuzanna Wyleciał ,&nbsp;Jarosław Zalewski ,&nbsp;Jadwiga Nessler\",\"doi\":\"10.1016/j.advms.2024.02.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>Heart failure (HF) with improved ejection fraction (HFimpEF) is a new category of HF introduced in the newest European Society of Cardiology guidelines. However, clinical characteristics and long-term outcomes of HFimpEF patients remain insufficiently elucidated. We sought to characterize Polish HFimpEF patients and determine their long-term mortality.</p></div><div><h3>Material and methods</h3><p>Of 1186 patients enrolled in the single-center Lesser Poland Cracovian Heart Failure (LECRA-HF) registry between 2009 and 2019 and hospitalized due to HF decompensation, 340 (28.7%) were those with HF with reduced ejection fraction (HFrEF). Based on follow-up echocardiography, 61 (17.9%) of them were classified as HFimpEF and the remaining as HFnon-impEF.</p></div><div><h3>Results</h3><p>HFimpEF patients were more frequently females (P ​&lt; ​0.001), had higher baseline left ventricular ejection fraction (LVEF, P ​&lt; ​0.001), had less often a history of diabetes (P ​= ​0.024), severe chronic kidney disease (P ​= ​0.026) or prior myocardial infarction (P ​= ​0.008) than HFnon-impEF patients. By multivariable analysis the HFimpEF diagnosis was independently predicted by baseline NYHA I/II (odds ratio [OR] 2.347, 95% confidence interval [95%CI] 1.020–5.405), non-ischemic etiology (OR 3.096, 95%CI 1.587–6.024), lack of diabetes mellitus (OR 2.016, 95%CI 1.059–3.846) and higher baseline LVEF (OR 1.084, 95%CI 1.042–1.126, per 1%). Within the median 49 (25–77) months all-cause mortality was lower in HFimpEF than in HFnon-impEF (10.8 vs 16.4%/year, P ​= ​0.004).</p></div><div><h3>Conclusions</h3><p>Our findings indicate that every sixth Polish patient with HFrEF has a chance to improve LVEF during follow-up and to become a HFimpEF patient. Baseline characteristics of HFimpEF patients are different from HFnon-impEF. Simultaneously, the HFimpEF diagnosis is associated with higher long-term survival.</p></div>\",\"PeriodicalId\":7347,\"journal\":{\"name\":\"Advances in medical sciences\",\"volume\":\"69 1\",\"pages\":\"Pages 132-138\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in medical sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1896112624000130\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in medical sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1896112624000130","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:射血分数改善型心力衰竭(HFimpEF)是欧洲心脏病学会最新指南中引入的一个新的心力衰竭类别。然而,HFimpEF 患者的临床特征和长期预后仍未得到充分阐明。我们试图描述波兰 HFimpEF 患者的特征,并确定其长期死亡率:2009年至2019年期间,1186名患者加入了小波兰克拉科夫心力衰竭(LECRA-HF)单中心登记,并因心力衰竭失代偿而住院治疗,其中340人(28.7%)为射血分数降低型心力衰竭(HFrEF)患者。根据随访超声心动图,其中61人(17.9%)被归类为HFimpEF,其余为HFnon-impEF:结果:HFimpEF 患者多为女性(P 结论:HFimpEF 患者多为女性:我们的研究结果表明,每六名波兰 HFrEF 患者都有机会在随访期间改善 LVEF,成为 HFimpEF 患者。HFimpEF 患者的基线特征与非 HFimpEF 患者不同。同时,HFimpEF诊断与较高的长期生存率相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical characteristics and long-term outcomes of patients with heart failure with improved ejection fraction. First Polish experience from LECRA-HF registry

Purpose

Heart failure (HF) with improved ejection fraction (HFimpEF) is a new category of HF introduced in the newest European Society of Cardiology guidelines. However, clinical characteristics and long-term outcomes of HFimpEF patients remain insufficiently elucidated. We sought to characterize Polish HFimpEF patients and determine their long-term mortality.

Material and methods

Of 1186 patients enrolled in the single-center Lesser Poland Cracovian Heart Failure (LECRA-HF) registry between 2009 and 2019 and hospitalized due to HF decompensation, 340 (28.7%) were those with HF with reduced ejection fraction (HFrEF). Based on follow-up echocardiography, 61 (17.9%) of them were classified as HFimpEF and the remaining as HFnon-impEF.

Results

HFimpEF patients were more frequently females (P ​< ​0.001), had higher baseline left ventricular ejection fraction (LVEF, P ​< ​0.001), had less often a history of diabetes (P ​= ​0.024), severe chronic kidney disease (P ​= ​0.026) or prior myocardial infarction (P ​= ​0.008) than HFnon-impEF patients. By multivariable analysis the HFimpEF diagnosis was independently predicted by baseline NYHA I/II (odds ratio [OR] 2.347, 95% confidence interval [95%CI] 1.020–5.405), non-ischemic etiology (OR 3.096, 95%CI 1.587–6.024), lack of diabetes mellitus (OR 2.016, 95%CI 1.059–3.846) and higher baseline LVEF (OR 1.084, 95%CI 1.042–1.126, per 1%). Within the median 49 (25–77) months all-cause mortality was lower in HFimpEF than in HFnon-impEF (10.8 vs 16.4%/year, P ​= ​0.004).

Conclusions

Our findings indicate that every sixth Polish patient with HFrEF has a chance to improve LVEF during follow-up and to become a HFimpEF patient. Baseline characteristics of HFimpEF patients are different from HFnon-impEF. Simultaneously, the HFimpEF diagnosis is associated with higher long-term survival.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in medical sciences
Advances in medical sciences 医学-医学:研究与实验
CiteScore
5.00
自引率
0.00%
发文量
53
审稿时长
25 days
期刊介绍: Advances in Medical Sciences is an international, peer-reviewed journal that welcomes original research articles and reviews on current advances in life sciences, preclinical and clinical medicine, and related disciplines. The Journal’s primary aim is to make every effort to contribute to progress in medical sciences. The strive is to bridge laboratory and clinical settings with cutting edge research findings and new developments. Advances in Medical Sciences publishes articles which bring novel insights into diagnostic and molecular imaging, offering essential prior knowledge for diagnosis and treatment indispensable in all areas of medical sciences. It also publishes articles on pathological sciences giving foundation knowledge on the overall study of human diseases. Through its publications Advances in Medical Sciences also stresses the importance of pharmaceutical sciences as a rapidly and ever expanding area of research on drug design, development, action and evaluation contributing significantly to a variety of scientific disciplines. The journal welcomes submissions from the following disciplines: General and internal medicine, Cancer research, Genetics, Endocrinology, Gastroenterology, Cardiology and Cardiovascular Medicine, Immunology and Allergy, Pathology and Forensic Medicine, Cell and molecular Biology, Haematology, Biochemistry, Clinical and Experimental Pathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信